“I explained to her that it’s in tiny, tiny print, and it’s in some page of the paper that no one is going to read. But it felt to her like she was just standing out there in public with a ‘TRANS’ sign on her.”

— The mother of a Wisconsin transgender teenager who was terrified when the process required to legally change her name meant publishing both her old and new names in a local paper for three weeks, thus publicizing her transition.

Lawyers said Wisconsin’s public name-change process creates a dataset of likely transgender people, exposing them to risks of discrimination, harassment or violence. 

Illustration by Dadu Shin, special to ProPublica 

Glenmark Pharmaceuticals has recalled two dozen generic medicines sold to American patients because the Indian factory that made them failed to comply with U.S. manufacturing standards and the Food and Drug Administration determined that the faulty drugs could harm people, federal records show.

In February, the FDA found problems with cleaning and testing at the plant in Madhya Pradesh, India, which was the subject of a ProPublica investigation last year. The current recalls, listed in an FDA enforcement report last week, cover a wide range of commonly prescribed medicines, including ones that treat epilepsy, diabetes, multiple sclerosis, heart disease and high blood pressure, among other ailments. 

A Glenmark spokesperson said in a statement the company was “committed to working diligently with the FDA to ensure compliance with manufacturing operations and quality systems.”